Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate

Biotech Targets Triple-Negative Breast Cancer and Lymphoma

 
• By Andrew McConaghie

The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.

Merck KGaA Darmstadt
Merck KGaA has licensed the drug to Diaccurate, but will maintain an active interest in the compound, and has taken a stakeholding in the biotech.

More from Business

More from Scrip